With one drug taking on average 2 billion dollars and 15 years to get to the market, the hunt is on for already existing FDA-approved drugs for purposes (indications) other than those they were approved for. Our lab intends to develop a ‘multi-omics’ stack that brings together genomics and other genome-scale datasets that is also integrated with clinical data available at our partner hospitals. This rich and integrated corpus of knowledge, using systems biology tools, will enable us to predict:
1) New therapeutic targets and pathways.
2) Novel and repurposed drug candidates that can enhance cancer patient outcomes in the local population.